MicroRNAs as Potential Biomarkers for Chemoresistance in Adenocarcinomas of the Esophagogastric Junction

Christina Just, Juliana Knief, Pamela Lazar-Karsten, Ekaterina Petrova, Richard Hummel, Christoph Röcken, Ulrich Wellner, Christoph Thorns, Kenneth J. Vega

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Concerning adenocarcinomas of the esophagogastric junction, neoadjuvant chemotherapy is regularly implemented, but patients' response varies greatly, with some cases showing no therapeutic effect, being deemed as chemoresistant. Small, noncoding RNAs (miRNAs) have evolved as key players in biological processes, including malignant diseases, often promoting tumor growth and expansion. In addition, specific miRNAs have been implicated in the development of chemoresistance through evasion of apoptosis, cell cycle alterations, and drug target modification. We performed a retrospective study of 33 patients receiving neoadjuvant chemotherapy by measuring their miRNA expression profiles. Histologic tumor regression was evaluated using resection specimens, while miRNA profiles were prepared using preoperative biopsies without prior therapy. A preselected panel of 96 miRNAs, known to be of importance in various malignancies, was used to test for significant differences between responsive (chemosensitive) and nonresponsive (chemoresistant) cases. The cohort consisted of 12 nonresponsive and 21 responsive cases with the following 4 miRNAs differentially expressed between both the groups: hsa-let-7f-5p, hsa-miRNA-221-3p, hsa-miRNA-31-5p, and hsa-miRNA-191-5p. The former 3 showed upregulation in chemoresistant cases, while the latter showed upregulation in chemosensitive cases. In addition, significant correlation between high expression of hsa-miRNA-194-5p and prolonged survival could be demonstrated (p value <0.0001). In conclusion, we identified a panel of 3 miRNAs predicting chemoresistance and a single miRNA contributing to chemosensitivity. These miRNAs might function as prognostic biomarkers and enable clinicians to better predict the effect of one or more reliably select patients benefitting from (neoadjuvant) chemotherapy.

Original languageEnglish (US)
Article number4903152
JournalJournal of Oncology
Volume2019
DOIs
StatePublished - Jan 1 2019

Fingerprint

Esophagogastric Junction
MicroRNAs
Adenocarcinoma
Biomarkers
Drug Therapy
Up-Regulation
Biological Phenomena
Small Untranslated RNA
Neoplasms
Therapeutic Uses
Cell Cycle

ASJC Scopus subject areas

  • Oncology

Cite this

MicroRNAs as Potential Biomarkers for Chemoresistance in Adenocarcinomas of the Esophagogastric Junction. / Just, Christina; Knief, Juliana; Lazar-Karsten, Pamela; Petrova, Ekaterina; Hummel, Richard; Röcken, Christoph; Wellner, Ulrich; Thorns, Christoph; Vega, Kenneth J.

In: Journal of Oncology, Vol. 2019, 4903152, 01.01.2019.

Research output: Contribution to journalArticle

Just, C, Knief, J, Lazar-Karsten, P, Petrova, E, Hummel, R, Röcken, C, Wellner, U, Thorns, C & Vega, KJ 2019, 'MicroRNAs as Potential Biomarkers for Chemoresistance in Adenocarcinomas of the Esophagogastric Junction', Journal of Oncology, vol. 2019, 4903152. https://doi.org/10.1155/2019/4903152
Just, Christina ; Knief, Juliana ; Lazar-Karsten, Pamela ; Petrova, Ekaterina ; Hummel, Richard ; Röcken, Christoph ; Wellner, Ulrich ; Thorns, Christoph ; Vega, Kenneth J. / MicroRNAs as Potential Biomarkers for Chemoresistance in Adenocarcinomas of the Esophagogastric Junction. In: Journal of Oncology. 2019 ; Vol. 2019.
@article{342160b3985d459f9d4d84da731842b7,
title = "MicroRNAs as Potential Biomarkers for Chemoresistance in Adenocarcinomas of the Esophagogastric Junction",
abstract = "Concerning adenocarcinomas of the esophagogastric junction, neoadjuvant chemotherapy is regularly implemented, but patients' response varies greatly, with some cases showing no therapeutic effect, being deemed as chemoresistant. Small, noncoding RNAs (miRNAs) have evolved as key players in biological processes, including malignant diseases, often promoting tumor growth and expansion. In addition, specific miRNAs have been implicated in the development of chemoresistance through evasion of apoptosis, cell cycle alterations, and drug target modification. We performed a retrospective study of 33 patients receiving neoadjuvant chemotherapy by measuring their miRNA expression profiles. Histologic tumor regression was evaluated using resection specimens, while miRNA profiles were prepared using preoperative biopsies without prior therapy. A preselected panel of 96 miRNAs, known to be of importance in various malignancies, was used to test for significant differences between responsive (chemosensitive) and nonresponsive (chemoresistant) cases. The cohort consisted of 12 nonresponsive and 21 responsive cases with the following 4 miRNAs differentially expressed between both the groups: hsa-let-7f-5p, hsa-miRNA-221-3p, hsa-miRNA-31-5p, and hsa-miRNA-191-5p. The former 3 showed upregulation in chemoresistant cases, while the latter showed upregulation in chemosensitive cases. In addition, significant correlation between high expression of hsa-miRNA-194-5p and prolonged survival could be demonstrated (p value <0.0001). In conclusion, we identified a panel of 3 miRNAs predicting chemoresistance and a single miRNA contributing to chemosensitivity. These miRNAs might function as prognostic biomarkers and enable clinicians to better predict the effect of one or more reliably select patients benefitting from (neoadjuvant) chemotherapy.",
author = "Christina Just and Juliana Knief and Pamela Lazar-Karsten and Ekaterina Petrova and Richard Hummel and Christoph R{\"o}cken and Ulrich Wellner and Christoph Thorns and Vega, {Kenneth J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1155/2019/4903152",
language = "English (US)",
volume = "2019",
journal = "Journal of Oncology",
issn = "1687-8450",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - MicroRNAs as Potential Biomarkers for Chemoresistance in Adenocarcinomas of the Esophagogastric Junction

AU - Just, Christina

AU - Knief, Juliana

AU - Lazar-Karsten, Pamela

AU - Petrova, Ekaterina

AU - Hummel, Richard

AU - Röcken, Christoph

AU - Wellner, Ulrich

AU - Thorns, Christoph

AU - Vega, Kenneth J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Concerning adenocarcinomas of the esophagogastric junction, neoadjuvant chemotherapy is regularly implemented, but patients' response varies greatly, with some cases showing no therapeutic effect, being deemed as chemoresistant. Small, noncoding RNAs (miRNAs) have evolved as key players in biological processes, including malignant diseases, often promoting tumor growth and expansion. In addition, specific miRNAs have been implicated in the development of chemoresistance through evasion of apoptosis, cell cycle alterations, and drug target modification. We performed a retrospective study of 33 patients receiving neoadjuvant chemotherapy by measuring their miRNA expression profiles. Histologic tumor regression was evaluated using resection specimens, while miRNA profiles were prepared using preoperative biopsies without prior therapy. A preselected panel of 96 miRNAs, known to be of importance in various malignancies, was used to test for significant differences between responsive (chemosensitive) and nonresponsive (chemoresistant) cases. The cohort consisted of 12 nonresponsive and 21 responsive cases with the following 4 miRNAs differentially expressed between both the groups: hsa-let-7f-5p, hsa-miRNA-221-3p, hsa-miRNA-31-5p, and hsa-miRNA-191-5p. The former 3 showed upregulation in chemoresistant cases, while the latter showed upregulation in chemosensitive cases. In addition, significant correlation between high expression of hsa-miRNA-194-5p and prolonged survival could be demonstrated (p value <0.0001). In conclusion, we identified a panel of 3 miRNAs predicting chemoresistance and a single miRNA contributing to chemosensitivity. These miRNAs might function as prognostic biomarkers and enable clinicians to better predict the effect of one or more reliably select patients benefitting from (neoadjuvant) chemotherapy.

AB - Concerning adenocarcinomas of the esophagogastric junction, neoadjuvant chemotherapy is regularly implemented, but patients' response varies greatly, with some cases showing no therapeutic effect, being deemed as chemoresistant. Small, noncoding RNAs (miRNAs) have evolved as key players in biological processes, including malignant diseases, often promoting tumor growth and expansion. In addition, specific miRNAs have been implicated in the development of chemoresistance through evasion of apoptosis, cell cycle alterations, and drug target modification. We performed a retrospective study of 33 patients receiving neoadjuvant chemotherapy by measuring their miRNA expression profiles. Histologic tumor regression was evaluated using resection specimens, while miRNA profiles were prepared using preoperative biopsies without prior therapy. A preselected panel of 96 miRNAs, known to be of importance in various malignancies, was used to test for significant differences between responsive (chemosensitive) and nonresponsive (chemoresistant) cases. The cohort consisted of 12 nonresponsive and 21 responsive cases with the following 4 miRNAs differentially expressed between both the groups: hsa-let-7f-5p, hsa-miRNA-221-3p, hsa-miRNA-31-5p, and hsa-miRNA-191-5p. The former 3 showed upregulation in chemoresistant cases, while the latter showed upregulation in chemosensitive cases. In addition, significant correlation between high expression of hsa-miRNA-194-5p and prolonged survival could be demonstrated (p value <0.0001). In conclusion, we identified a panel of 3 miRNAs predicting chemoresistance and a single miRNA contributing to chemosensitivity. These miRNAs might function as prognostic biomarkers and enable clinicians to better predict the effect of one or more reliably select patients benefitting from (neoadjuvant) chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85071129636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071129636&partnerID=8YFLogxK

U2 - 10.1155/2019/4903152

DO - 10.1155/2019/4903152

M3 - Article

AN - SCOPUS:85071129636

VL - 2019

JO - Journal of Oncology

JF - Journal of Oncology

SN - 1687-8450

M1 - 4903152

ER -